Lorazepam-Induced Toxicity in the Aged

• Status: Completed
• Trial end date: 2007-07-01
• Target enrollment: 0
• Participant gender: All

Summary

This study will compare the effects of an acute dose of lorazepam to a placebo in elderly patients with generalized anxiety disorder (GAD).

• Phase: Phase 4
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Nathan Kline Institute for Psychiatric Research
• Collaborator: National Institute of Mental Health (NIMH)
• Treatments: Lorazepam

Criteria

Inclusion Criteria:

• Lorazepam treatment for at least 3 months

• Cognitively intact

Note: Individuals who are unable or unwilling to have an MRI may be included

Exclusion Criteria:

• Major psychiatric disorder other than GAD

• Significant medical illness which may increase the likelihood of adverse reactions to lorazepam

• Severe loss of hearing or vision

• Current or past history of alcohol dependence

• Substance abuse within the past 6 months

• MRI evidence of infection, infarction, or other lesions suggestive of intervening neurological disease

• Clinical symptoms that suggest neurological disease

• Dementia or other mental syndromes or disorders